Lynx1 Capital Management LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Lynx1 Capital Management LP reported 14 stock positions worth $279.2 million. Its top holding was GH Research (GHRS) at 25.5% of the portfolio, followed by Merus (MRUS, 23.6%) and Protagonist Therapeutics (PTGX, 12.7%). Compared with Q4 2024, it opened 2 new positions, sold out of 6, added to 5 and reduced 2. The biggest buy was GH Research (GHRS, shares +33%) and the biggest sale an exit from Keros Therapeutics (KROS).
- Most Recent 13F
- Q2 2026
- Location
- DORADO, PR
- CIK
- 0001910456
- Portfolio Value
- $279.2M (Q1 2025)
- SEC Filing
- 0001892688-25-000120 ↗ filed May 15, 2025
Holdings Value
Holdings 14 stocks · $279.2M
| GHRS GH Research PLC | 25.45% | 6,443,940 | $71.1M | Add +32.6% |
| MRUS Merus NV | 23.65% | 1,568,841 | $66.0M | Reduce -0.8% |
| PTGX Protagonist Therapeutics Inc. | 12.69% | 733,014 | $35.4M | New |
| STOK Stoke Therapeutics Inc. | 12.60% | 5,291,929 | $35.2M | Add +2.0% |
| CGEM Cullinan Therapeutics Inc. | 8.72% | 3,215,722 | $24.3M | Add +155.7% |
| ALLO Allogene Therapeutics Inc. | 5.78% | 11,057,009 | $16.1M | Add +1.7% |
| CCCC C4 Therapeutics Inc. | 4.07% | 7,098,133 | $11.4M | Add +3.6% |
| TCRX Tscan Therapeutics Inc. | 2.65% | 5,357,347 | $7.4M | No change |
| DTIL Precision Biosciences Inc. | 1.31% | 766,051 | $3.7M | No change |
| IBIO Ibio Inc. | 1.24% | 862,279 | $3.5M | No change |
| PASG Passage Bio Inc. | 1.17% | 9,256,953 | $3.3M | No change |
| UPB Upstream Bio Inc. | 0.48% | 219,247 | $1.3M | Reduce -8.7% |
| NEUP Neuphoria Therapeutics Inc. | 0.09% | 45,806 | $264K | No change |
| DSGN Design Therapeutics Inc. | 0.09% | 65,954 | $255K | New |
Portfolio Sells Q4 2024 → Q1 2025
| KROS Keros Therapeutics Inc. | Sold out | 0.00% | −3.23 |
| ALLK Allakos LLC | Sold out | 0.00% | −1.65 |
| MRUS Merus NV | Reduce -0.8% | 23.65% | −1.28 |
| UPB Upstream Bio Inc. | Reduce -8.7% | 0.48% | −1.00 |
| CRBU Caribou Biosciences Inc. | Sold out | 0.00% | −0.41 |
| VOR Vor Biopharma Inc. | Sold out | 0.00% | −0.27 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −0.11 |
| RPTX Repare Therapeutics Inc. | Sold out | 0.00% | −0.04 |
Portfolio Buys Q4 2024 → Q1 2025
| GHRS GH Research PLC | Add +32.6% | 25.45% | +12.70 |
| PTGX Protagonist Therapeutics Inc. | New | 12.69% | +12.69 |
| CGEM Cullinan Therapeutics Inc. | Add +155.7% | 8.72% | +2.97 |
| DSGN Design Therapeutics Inc. | New | 0.09% | +0.09 |
| ALLO Allogene Therapeutics Inc. | Add +1.7% | 5.78% | −2.90 |
| CCCC C4 Therapeutics Inc. | Add +3.6% | 4.07% | −5.18 |
| STOK Stoke Therapeutics Inc. | Add +2.0% | 12.60% | −8.85 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026Amended | 27 | $865.5M | GHRS, CGEM, STOK, AGIO, CCCC |
| Q1 2026 | 23 | $632.7M | STOK, GHRS, CGEM, AGIO, DNLI |
| Q4 2025 | 22 | $494.0M | STOK, GHRS, CGEM, DNLI, CCCC |
| Q3 2025 | 14 | $491.3M | MRUS, STOK, GHRS, PTGX, CGEM |
| Q2 2025 | 15 | $346.2M | MRUS, GHRS, STOK, PTGX, CGEM |
| Q1 2025 | 14 | $279.2M | GHRS, MRUS, PTGX, STOK, CGEM |
| Q4 2024 | 18 | $266.7M | MRUS, STOK, GHRS, CCCC, ALLO |
| Q3 2024 | 18 | $282.2M | MRUS, STOK, CCCC, GHRS, TCRX |
| Q2 2024Amended | 17 | $277.2M | MRUS, STOK, GHRS, CCCC, TCRX |
| Q1 2024Amended | 16 | $388.2M | ALPN, MRUS, STOK, TCRX, CABA |